AUTHOR=Wang Wen-Wen , Zhang Man-Man , Zhang Xing-Ru , Zhang Zeng-Rui , Chen Jie , Feng Liang , Xie Cheng-Long 

TITLE=A Meta-Analysis of Adenosine A2A Receptor Antagonists on Levodopa-Induced Dyskinesia In Vivo

JOURNAL=Frontiers in Neurology

VOLUME=8

YEAR=2017

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2017.00702

DOI=10.3389/fneur.2017.00702

ISSN=1664-2295

ABSTRACT=<sec id="ST1"><title>Background</title><p>Long-term use of levodopa (<sc>l</sc>-dopa) is inevitably complicated with highly disabling fluctuations and drug-induced dyskinesias, which pose major challenges to the existing drug therapy of Parkinson’s disease.</p></sec><sec id="ST2"><title>Methods</title><p>In this study, we conducted a systematic review and meta-analysis to assess the efficacy of A2A receptor antagonists on reducing <sc>l</sc>-dopa-induced dyskinesias (LID).</p></sec><sec id="ST3"><title>Results</title><p>Nine studies with a total of 152 animals were included in this meta-analysis. Total abnormal involuntary movements (AIM) score, locomotor activity, and motor disability were reported as outcome measures in 5, 5, and 3 studies, respectively. Combined standardized mean difference (SMD) estimates were calculated using a random-effects model. We pooled the whole data and found that, when compared to <sc>l</sc>-dopa alone, A2A receptor antagonists plus <sc>l</sc>-dopa treatment showed no effect on locomotor activity (SMD −0.00, 95% confidence interval (CI): −2.52 to 2.52, <italic>p</italic> = 1.0), superiority in improvement of motor disability (SMD −5.06, 95% CI: −9.25 to −0.87, <italic>p</italic> = 0.02) and more effective in control of AIM (SMD −1.82, 95% CI: −3.38 to −0.25, <italic>p</italic> = 0.02).</p></sec><sec id="ST4"><title>Conclusion</title><p>To sum up, these results demonstrated that A2A receptor antagonists appear to have efficacy in animal models of LID. However, large randomized clinical trials testing the effects of A2A receptor antagonists in LID patients are always warranted.</p></sec>